Research & Development

R&D Overview Our R&D Approach Pipeline Technology Platforms Manufacturing

Other Information

Clinical Trials Early Access Investigator Sponsored Studies

Pipeline

Pipeline of Key Proprietary Products

We have a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer.

Development Candidates

Preclinical Phase 1 Phase 2 Phase 3 Regulatory
Review
ALKS 3831*
Schizophrenia / Bipolar I Disorder
Nemvaleukin alfa (Formerly ALKS 4230)
Oncology
Selective HDAC Inhibitors
ALKS 1140
Neurology (Orphan)
Neurology/Neuropsychiatry (Non-Orphan)
Frontotemporal Dementia
Oncology
Orexin 2 Receptor Agonist
Narcolepsy
Tumor-targeted Split IL-12
Oncology
IL-18
Oncology
*PDUFA target action date of NDA resubmission: June 1, 2021
Oncology CNS